Intravitreal bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization overlying choroidal osteoma.

Abstract

PURPOSE:

To report the effect of anti-vascular endothelial growth factor (VEGF) therapy for choroidal neovascularization overlying choroidal osteoma.

METHOD:

In an interventional case report, intravitreal anti-VEGF therapy was used for tumor-related choroidal neovascularization.

RESULTS:

A 34-year-old woman with bilateral choroidal osteoma had a decrease in visual acuity in the right eye from 20/30 to 20/100. Ophthalmoscopy revealed partially decalcified circumpapillary, macular choroidal osteoma with overlying subretinal hemorrhage and choroidal neovascular membrane. Intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) resulted in membrane regression and visual acuity improvement to 20/50 at 6 weeks. Further therapy with intravitreal ranibizumab (Lucentis; Genentech, Inc.) resolved persistent subretinal fluid, and visual acuity improved to 20/30 at the 6-month follow-up.

CONCLUSIONS:

Therapy with intravitreal anti-VEGF medications might be an alternative for patients with choroidal neovascularization overlying choroidal osteoma.

• Authors: Carol L Shields, Pedro F Salazar, Hakan Demirci, William E Benson, Jerry A Shields
• Journal: Retinal cases & brief reports (Retin Cases Brief Rep) Vol. 2 Issue 1 Pg. 18-20 ( 2008) ISSN: 1935-1089 [Print] United States
• PMID: 25389607 (Publication Type: Journal Article)